Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$88.76 USD

88.76
5,165,991

-0.24 (-0.27%)

Updated Oct 28, 2024 04:00 PM ET

After-Market: $88.76 0.00 (0.00%) 6:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss

Sanofi (SNY) beats earnings but misses on sales in the second quarter of 2018 owing to currency headwinds and struggling diabetes and cardiovascular unit.

    Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

    Is (GILD) Outperforming Other Medical Stocks This Year?

      Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan

      Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics. The board authorizes a new $2.0 billion share buyback plan.

        AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up

        AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.

          Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up

          ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.

            Microsoft, H&R Block, Facebook, Qualcomm and Gilead highlighted as Zacks Bull and Bear of the Day

            Microsoft, H&R Block, Facebook, Qualcomm and Gilead highlighted as Zacks Bull and Bear of the Day

              Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit

              Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.

                Mark Vickery headshot

                Facebook Misses 1st Time in 11 Quarters; Plus GILD, QCOM

                Facebook has posted a one-penny miss, but revenues also came in lower than expected.

                  Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates

                  Gilead (GILD) delivered earnings and revenue surprises of 23.23% and 9.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                    Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug

                    The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.

                      Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?

                      Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret, might lead the company to an earnings beat in the second quarter.

                        Is a Beat in Store for Keryx (KERX) This Earnings Season?

                        Keryx (KERX) is likely to provide updates on the merger with Akebia along with the updates on Auryxia at the second quarter call.

                          Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK

                          The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.

                            Implied Volatility Surging for Gilead Sciences (GILD) Stock Options

                            Investors need to pay close attention to Gilead Sciences (GILD) stock based on the movements in the options market lately.

                              Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?

                              Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.

                                Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                                Alexion is likely to provide details about the pipeline portfolio when it reports its second-quarter 2018 results on Jul 26.

                                  Sweta Killa headshot

                                  Healthcare ETFs to Buy on Solid Q2 Earnings Expectations

                                  With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 9.1% in the second quarter, suggesting continued outperformance for healthcare ETFs.

                                    Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?

                                    While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

                                      Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?

                                      Gilead (GILD) is likely to beat expectations in the second quarter propelled by the momentum in the HIV franchise.

                                        Madhu Goel headshot

                                        4 Biotech Bets to Watch as Industry Rebounds in a Month

                                        The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.

                                          5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates

                                          Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.

                                            J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

                                            The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.

                                              The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna

                                              The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna

                                                Is Invesco Zacks Multi-Asset Income ETF (CVY) a Hot ETF Right Now?

                                                Smart Beta ETF report for CVY

                                                  Sweta Killa headshot

                                                  Biotech ETFs Surge on Biogen's Positive Drug Trial Result

                                                  Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.